NPC-9902
Regimen
- Experimental
- 2×2 factorial: accelerated fractionation (AF, 6 fractions/week) ± concurrent cisplatin/5-FU; AF+C arm vs conventional fractionation (CF) alone reference
- Control
- Conventional fractionation (CF) RT alone
Population
T3-4N0-1M0 NPC (locoregional advanced, node-limited disease), Hong Kong multicentre
Key finding
Factorial design tested whether adding concurrent chemo, accelerating fractionation, or both improved outcomes in T3-4N0-1 NPC. The interaction of CRT and AF was strongly synergistic (interaction p=0.006), with the AF+C arm achieving 94% 3-year FFS. Neither AF alone nor CCRT alone significantly outperformed RT alone in this T3-4N0-1 specific population, reflecting that the CCRT benefit seen in N2-3 disease (NPC-9901) may not extrapolate directly to node-limited disease. Trial terminated early due to slow accrual.
Source: PMID 16904519